Brief: Reviva Announces FDA Alignment On Brilaroxazine Clinical Trials For NDA In Schizophrenia

Reviva Pharmaceuticals Holdings

15/04/2024 13:35

April 15 (Reuters) - Reviva Pharmaceuticals Holdings,
Inc.  RVPH.O :
    * REVIVA PHARMACEUTICALS HOLDINGS, INC. - OPLINE DATA FROM
1-YEAR
OPEN-LABEL EXTENSION (OLE) LONG-TERM SAFETY TRIAL EXPECTED IN Q4
2024
    * REVIVA ANNOUNCES FDA ALIGNMENT ON BRILAROXAZINE CLINICAL
TRIALS
FOR NDA IN SCHIZOPHRENIA
    * REVIVA PHARMACEUTICALS HOLDINGS, INC. - FDA ACCEPTANCE OF
4-WEEK
GLOBAL REGISTRATIONAL PHASE 3 RECOVER-2 STUDY
    * REVIVA PHARMACEUTICALS HOLDINGS, INC. - GAINED ALIGNMENT
WITH
FDA ON ITS REGISTRATIONAL PHASE 3 PROGRAM FOR BRILAROXAZINE IN
SCHIZOPHRENIA
    * REVIVA PHARMACEUTICALS HOLDINGS, INC. - FDA ACCEPTED A
4-WEEK
RECOVER-2 STUDY FOR BRILAROXAZINE IN SCHIZOPHRENIA
    * REVIVA PHARMACEUTICALS HOLDINGS- FDA INDICATED IT WILL
REQUIRE A
LONG-TERM RANDOMIZED WITHDRAWAL STUDY POST-APPROVAL TO SUPPORT
MAINTENANCE OF EFFECT

Source text for Eikon:  ID:nGNX4g2M19 
Further company coverage:  RVPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))